

Nanoemulsion-Based Phytopharmaceutical Approaches of *Anthocephalus cadamba* for the Management of Pain and Inflammation: A Comprehensive Review

Riya Jaitwar *, Urwashi Ghughre¹, Diksha Bais²

*Research Scholler at Gondia College of Pharmacy Chulod, Gondia Mh

¹Assistant Professor at Gondia College of Pharmacy Chulod, Gondia Mh.

²Assistant Professor at Gondia College of Pharmacy Chulod, Gondia Mh

ABSTRACT

Pain and inflammatory disorders are among the most prevalent health problems worldwide and are commonly managed using non-steroidal anti-inflammatory drugs and corticosteroids, which are often associated with adverse effects during long-term use. Medicinal plants offer a promising alternative due to their safety and multi-targeted therapeutic potential. *Anthocephalus cadamba* has been traditionally used for the treatment of pain, inflammation, fever, wounds, and related disorders, and its bark is rich in bioactive phytoconstituents with proven pharmacological activities. However, the therapeutic application of conventional *A. cadamba* bark extract is limited by poor solubility, low bioavailability, and stability issues. Nanoemulsion-based drug delivery systems have emerged as an effective approach to overcome these limitations by enhancing solubility, bioavailability, and therapeutic consistency of herbal extracts. This review summarizes the botanical profile, ethnomedicinal uses, phytochemical constituents, and pharmacological activities of *Anthocephalus cadamba* bark, with a particular focus on its anti-inflammatory and analgesic potential. The review also highlights the formulation strategies, evaluation parameters, safety considerations, and future prospects of nanoemulsion-based delivery of *A. cadamba* bark extract for the management of pain and inflammatory disorders.

Keywords: *Anthocephalus cadamba*; Nanoemulsion; Phytopharmaceuticals; Pain; Inflammation; Novel drug delivery system.

INTRODUCTION

- **Global burden of pain and inflammatory disorders:**

Pain and inflammation are among the most common clinical conditions worldwide, affecting individuals of all age groups. Chronic inflammatory diseases such as arthritis, musculoskeletal disorders, and autoimmune conditions significantly impair daily functioning and quality of life. The increasing prevalence of lifestyle-related disorders and aging populations has further intensified the global burden of pain and inflammation, creating a continuous demand for effective and long-term therapeutic interventions.

- **Limitations of conventional NSAIDs and steroid therapy:**

Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are widely prescribed for the management of pain and inflammation. Despite their effectiveness, prolonged use of these drugs is often associated with serious adverse effects, including gastrointestinal ulceration, renal toxicity, cardiovascular complications, and immunosuppression. These safety concerns limit their long-term use and emphasize the need for safer therapeutic alternatives.

- **Rising interest in medicinal plants and phytopharmaceuticals:**

Medicinal plants have been used for centuries in traditional systems of medicine to treat

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

pain and inflammatory conditions. In recent years, scientific validation of these traditional remedies has renewed interest in plant-based drugs. Phytopharmaceuticals are considered advantageous due to their natural origin, structural diversity, relatively lower toxicity, and potential for multi-targeted therapeutic effects.

- **Importance of novel drug delivery systems (NDDS) in herbal medicine:**

Although herbal extracts possess significant pharmacological activity, their clinical application is often limited by poor aqueous solubility, low bioavailability, instability, and inconsistent therapeutic outcomes. Novel drug delivery systems (NDDS) such as nanoemulsions, nanoparticles, liposomes, and phytosomes have emerged as effective strategies to overcome these limitations by enhancing solubility, stability, permeability, and controlled drug release of phytoconstituents.

- **Rationale for selecting Anthocephalus cadamba:**

Anthocephalus cadamba (Kadamba) is a well-known medicinal plant traditionally used for the treatment of pain, inflammation, fever, wounds, and various inflammatory disorders. The bark of the plant is rich in bioactive compounds including alkaloids, flavonoids, triterpenoids, and phenolic constituents, which have demonstrated significant anti-inflammatory and analgesic activities in experimental studies. However, its therapeutic potential remains underutilized due to formulation and bioavailability challenges.

- **Scope and objectives of the review:**

The present review aims to compile and critically analyze available literature on the phytochemical composition and pharmacological activities of *Anthocephalus cadamba* bark, with a specific focus on pain and inflammation. Furthermore, the review highlights the role of nanoemulsion-based drug delivery systems in enhancing the

therapeutic efficacy of herbal extracts and discusses future prospects for the development of *A. cadamba* bark nanoemulsion as a novel phytopharmaceutical for pain and inflammatory disorders.

2. Botanical and Ethnomedicinal Profile of *Anthocephalus cadamba*



Diagram 1: *Anthocephalus cadamba*

2.1 Botanical Classification

Anthocephalus cadamba (Roxb.) Miq. is a medicinally important tree belonging to the Rubiaceae family. The plant falls under the genus *Anthocephalus* and the species *cadamba*. It is commonly referred to as Kadamba in India and is known internationally as the Burflower Tree. The plant is characterized by its tall growth, broad leaves, and distinctive spherical flowers.

2.2 Geographical Distribution

The tree is widely distributed throughout India, particularly in tropical and subtropical regions. It is also commonly found in several Southeast Asian countries, including Indonesia, Malaysia, Thailand, and Nepal. Due to its wide availability and therapeutic value, *A. cadamba* has been extensively used in various traditional medicinal systems, especially in Ayurveda and local folk medicine.

2.3 Traditional and Ethnomedicinal Uses

Traditionally, the bark of *Anthocephalus cadamba* has been used for the treatment of pain and inflammatory conditions, such as swelling and joint discomfort. In folk medicine, bark decoctions are commonly administered to manage fever. The bark paste is also

applied externally to wounds to accelerate healing and prevent infection. Additionally, the plant has been traditionally used in the management of anemia, suggesting its role in improving blood-related disorders. Its use in treating infectious diseases further highlights its antimicrobial and immune-supportive properties.

Table 1: Botanical and Ethnomedicinal Profile of *Anthocephalus cadamba*

Parameter	Description
Botanical name	<i>Anthocephalus cadamba</i> (Roxb.) Miq.
Family	Rubiaceae
Common names	Kadamba, Burflower Tree
Plant part used	Bark
Geographical distribution	India, Southeast Asia
Traditional uses	Pain, inflammation, fever, wounds, anemia, infections
System of medicine	Ayurveda, folk medicine

3. Phytochemical Constituents of *Anthocephalus cadamba* Bark

Phytochemical analysis of *A. cadamba* bark has revealed the presence of a variety of bioactive secondary metabolites responsible for its pharmacological effects. Among these, alkaloids, particularly cadambine, are considered key constituents contributing to the plant's therapeutic activity. The bark also contains flavonoids, which are known for their antioxidant and anti-inflammatory properties.

In addition, triterpenoids and saponins present in the bark play an important role in reducing inflammation and supporting tissue repair. Phenolic compounds contribute to free radical scavenging activity, thereby reducing oxidative stress associated with inflammatory and painful conditions. The combined action of these phytoconstituents is believed to be responsible for the analgesic and anti-inflammatory effects of the bark extract.

Various solvents such as methanol, ethanol, hydroalcoholic mixtures, and water have been

employed for extracting these compounds. Organic solvents generally provide higher extraction yields and better recovery of alkaloids and flavonoids compared to aqueous extracts.

4. Pharmacological Activities Relevant to Pain and Inflammation

4.1 Anti-Inflammatory Activity

Several experimental studies have demonstrated the anti-inflammatory potential of *Anthocephalus cadamba* bark extracts using established in vivo animal models. In the carrageenan-induced paw edema model, the bark extract showed a marked reduction in paw swelling, indicating inhibition of acute inflammatory responses. Similarly, in the cotton pellet-induced granuloma model, the extract effectively suppressed granuloma formation, reflecting its activity against chronic inflammation.

The anti-inflammatory effect of the bark extract is attributed to multiple mechanisms, including inhibition of cyclooxygenase enzymes, leading to reduced prostaglandin production. Additionally, modulation of pro-inflammatory cytokines and enhancement of antioxidant defense mechanisms play a significant role in controlling inflammation.

4.2 Analgesic Activity

The analgesic properties of *A. cadamba* bark extract have been evaluated using both central and peripheral pain models. In central analgesic tests such as the hot plate and tail flick methods, the extract increased pain reaction time, suggesting central nervous system involvement. In the acetic acid-induced writhing test, a significant decrease in writhing responses was observed, indicating peripheral analgesic activity. These findings suggest that the bark extract exerts a broad-spectrum analgesic effect through multiple pain-modulating pathways.

4.3 Additional Supportive Activities

Apart from its primary analgesic and anti-inflammatory effects, *Anthocephalus cadamba* bark exhibits strong antioxidant activity, which helps protect tissues from oxidative damage. The bark has also shown wound healing potential, possibly through



enhanced collagen formation and reduced inflammation at the wound site. Furthermore, reported immunomodulatory effects support its traditional use in inflammatory and infectious conditions.

Table 2: Pharmacological Activities of Anthocephalus cadamba Bark Relevant to Pain and Inflammation

Activity	Experimental model	Observed effect
Anti-inflammatory	Carrageenan-induced paw edema	Reduction in acute inflammation
Anti-inflammatory	Cotton pellet granuloma	Suppression of chronic inflammation
Analgesic (central)	Hot plate, tail flick tests	Increased pain reaction time
Analgesic (peripheral)	Acetic acid-induced writhing	Decreased writhing response
Antioxidant	In vitro assays	Free radical scavenging
Wound healing	Excision/incision models	Enhanced tissue repair

5. Limitations of Conventional Anthocephalus cadamba Extract Formulations

- **Poor aqueous solubility:** Many of the active phytoconstituents present in Anthocephalus cadamba bark exhibit low solubility in water. This limits their dissolution in biological fluids and reduces the amount of drug available for absorption, ultimately affecting therapeutic effectiveness.
- **Low bioavailability:** Conventional formulations of A. cadamba bark extract often show poor bioavailability due to limited absorption, rapid metabolism, and insufficient permeability across biological membranes. As a result, only a small fraction of the active compounds reaches the target site.
- **Stability issues:** Herbal extracts are prone to degradation when exposed to environmental factors such as light, heat, moisture, and oxygen. These stability problems can lead to loss of phytochemical content over time, reducing the potency and shelf life of conventional A. cadamba formulations.

- **Variable therapeutic response:** The therapeutic outcome of traditional A. cadamba extract formulations may vary due to differences in plant source, harvesting conditions, extraction techniques, and phytochemical composition. Such variability makes it difficult to achieve consistent and reproducible therapeutic effects.
- **Need for advanced delivery systems:** Owing to the limitations associated with solubility, bioavailability, stability, and consistency, there is a strong need for advanced drug delivery approaches. Novel systems, particularly nano-based formulations, can improve drug solubility, protect bioactive compounds, enhance absorption, and ensure a more predictable therapeutic response.

6. Nanoemulsion as a Novel Drug Delivery System

- **Concept and definition of nanoemulsion:** Nanoemulsions are kinetically stable, heterogeneous systems composed of oil, water, surfactant, and co-surfactant, with droplet sizes typically in the nanometer range. Their small droplet size provides a large surface area, which enhances interaction with



biological membranes and improves drug delivery performance.

- **Types of nanoemulsions:**

Nanoemulsions are broadly classified into oil-in-water (O/W), water-in-oil (W/O), and bi-continuous systems. Among these, O/W nanoemulsions are commonly preferred for herbal drug delivery due to their better patient acceptability and ease of administration.

- **Advantages over conventional formulations:**

Compared to traditional dosage forms, nanoemulsions offer improved solubility for poorly water-soluble phytoconstituents, enhanced drug absorption, and faster onset of action. Their nano-sized droplets also contribute to improved physical stability and uniform drug distribution.

- **Role of nanoemulsion in phytopharmaceutical delivery:**

In herbal medicine, nanoemulsions play a crucial role in protecting sensitive phytochemicals from degradation and improving their bioavailability. Encapsulation of plant extracts in nanoemulsion systems helps in overcoming limitations such as poor solubility, instability, and inconsistent therapeutic response associated with conventional herbal formulations.

- **Enhanced permeability and bioavailability:**

The small droplet size of nanoemulsions facilitates better penetration across biological barriers, including skin and mucosal membranes. This leads to improved bioavailability of bioactive compounds, making nanoemulsions particularly suitable for topical, transdermal, and oral delivery of herbal drugs.

- **Controlled and targeted drug delivery potential:**

Nanoemulsion systems can be designed to provide controlled release of encapsulated phytoconstituents, thereby maintaining

therapeutic drug levels for extended periods. Additionally, they offer potential for site-specific delivery, reducing systemic exposure and minimizing adverse effects.


- **Relevance of nanoemulsion for pain and inflammation management:**

Nanoemulsion-based formulations have shown promising results in enhancing the anti-inflammatory and analgesic efficacy of plant-derived compounds. Improved penetration, sustained release, and better bioavailability make nanoemulsions an effective delivery system for managing pain and inflammatory conditions.

- **Suitability for Anthocephalus cadamba bark extract:**

Considering the solubility and bioavailability challenges associated with A. cadamba bark extract, nanoemulsion-based delivery represents a rational and effective approach. Incorporation of the extract into a nanoemulsion system is expected to enhance its therapeutic performance, stability, and clinical applicability in pain and inflammation management.

Diagram 2: Nanoemulsion structure



7. Nanoemulsion Formulation Strategies for Herbal Extracts

- **Selection of oil phase:**

The choice of oil plays a crucial role in nanoemulsion formulation, as it determines




the solubility of lipophilic phytoconstituents and overall formulation stability. Natural oils, medium-chain triglycerides, and pharmaceutically acceptable synthetic oils are commonly used depending on the solubility profile of the herbal extract.

- **Choice of surfactant and co-surfactant:** Surfactants and co-surfactants are essential for reducing interfacial tension and stabilizing nano-sized droplets. Non-ionic surfactants are generally preferred for herbal formulations due to their low toxicity and better biocompatibility. Co-surfactants further enhance flexibility of the interfacial film and assist in forming stable nanoemulsions.
- **Aqueous phase composition:** The aqueous phase may contain purified water or buffer solutions to maintain pH stability. Proper selection of the aqueous phase is important to ensure compatibility with the herbal extract and to maintain formulation integrity during storage.
- **Method of nanoemulsion preparation:** Nanoemulsions can be prepared using **high-energy methods** such as high-pressure homogenization and ultrasonication, or **low-energy methods** like phase inversion temperature and spontaneous emulsification. The choice of method depends on formulation components, desired droplet size, and scalability.
- **Optimization of formulation parameters:** Formulation variables such as oil-to-water ratio, surfactant concentration, and mixing conditions must be optimized to achieve minimum droplet size, low polydispersity index, and good physical stability. Experimental design approaches are often employed to optimize these parameters efficiently.
- **Incorporation of herbal extract:** The herbal extract is incorporated either into the oil phase or aqueous phase based on its solubility characteristics. Proper

incorporation ensures uniform distribution of phytoconstituents and prevents precipitation or phase separation.

- **Stability considerations:** Nanoemulsion formulations should be evaluated for thermodynamic and physical stability under different storage conditions. Stability studies help in identifying potential issues such as creaming, coalescence, or phase separation.
- **Scalability and reproducibility:** For practical and commercial application, the formulation strategy must be scalable and reproducible. Selection of simple preparation methods and pharmaceutically acceptable excipients enhances the feasibility of large-scale production of herbal nanoemulsions.

Diagram 3: General Components of Herbal Nanoemulsion



8. Evaluation Parameters of Nanoemulsion Formulations

- **Droplet size and size distribution:** Droplet size is a critical parameter that influences the stability, bioavailability, and drug release behavior of nanoemulsions. A smaller and uniformly distributed droplet size enhances surface area and improves interaction with biological membranes. Size distribution is commonly expressed as the polydispersity index, where lower values indicate better uniformity.



- **Zeta potential:**
Zeta potential reflects the surface charge of nanoemulsion droplets and is an important indicator of physical stability. Adequate zeta potential values help prevent droplet aggregation by electrostatic repulsion, thereby maintaining formulation stability during storage.
- **pH measurement:**
The pH of the nanoemulsion should be compatible with the intended route of administration. Maintaining an appropriate pH is essential to ensure stability of phytoconstituents and to avoid irritation or degradation during use.
- **Viscosity and rheological behavior:**
Viscosity affects the flow properties, spreadability, and ease of administration of nanoemulsions. Rheological evaluation helps in understanding the formulation's behavior under stress and is particularly important for topical or transdermal applications.
- **Drug content and entrapment efficiency:**
Drug content analysis ensures uniform distribution of the herbal extract within the nanoemulsion. Entrapment efficiency indicates the proportion of phytoconstituents successfully incorporated into the formulation, which directly influences therapeutic efficacy.
- **In vitro drug release studies:**
Drug release studies are conducted to evaluate the release pattern of phytoconstituents from the nanoemulsion. These studies help in predicting in vivo performance and understanding whether the formulation provides immediate or sustained release.
- **Physical and thermodynamic stability studies:**
Stability studies assess the resistance of nanoemulsions to phase separation, creaming, cracking, or coalescence under different storage and stress conditions.

Thermodynamic stability testing ensures long-term reliability of the formulation.

- **Dilution and robustness testing:**
Nanoemulsions should remain stable upon dilution, especially for oral and topical applications. Robustness testing evaluates the ability of the formulation to maintain stability under variations in environmental and handling conditions.
- **Compatibility and safety assessment:**
Compatibility studies ensure that formulation components do not interact adversely with the herbal extract. Preliminary safety assessments, such as irritation studies for topical formulations, are essential to confirm suitability for biological use.

Table 4: Evaluation Parameters for Nanoemulsion-Based Phytopharmaceuticals

Parameter	Significance
Droplet size	Influences stability and absorption
Polydispersity index	Indicates size uniformity
Zeta potential	Predicts physical stability
pH	Ensures formulation compatibility
Viscosity	Affects spreadability and flow
Drug content	Confirms uniformity
In vitro release	Predicts in vivo performance
Stability studies	Ensures shelf life

10. Safety, Toxicity, and Regulatory Considerations

- **Safety evaluation of herbal nanoemulsions:**
Although herbal medicines are generally considered safe, the incorporation of plant extracts into nanoemulsion systems may alter their biological behavior. Therefore, thorough safety evaluation is essential to ensure that nano-sized formulations do not induce unexpected toxic effects.



- **Acute and sub-acute toxicity studies:** Acute toxicity studies are conducted to determine the safe dose range and immediate adverse effects of nanoemulsion formulations. Sub-acute toxicity studies further help in assessing potential organ toxicity and biochemical changes following repeated administration.
- **Skin irritation and sensitization studies:** For topical or transdermal nanoemulsion formulations, skin irritation and sensitization studies are crucial. These evaluations confirm that the formulation does not cause redness, inflammation, or allergic reactions upon application.
- **Impact of nanocarrier components:** The safety of nanoemulsions is also influenced by the type and concentration of oils, surfactants, and co-surfactants used. Selection of pharmaceutically acceptable and biocompatible excipients is essential to minimize toxicity risks.
- **Regulatory challenges and standardization:** Regulatory approval of herbal nanoformulations faces challenges due to variability in phytochemical composition, lack of standardized manufacturing processes, and limited regulatory guidelines specific to nanotechnology-based herbal products.
- **Quality control and compliance:** Consistent quality control measures, including physicochemical characterization, stability testing, and batch-to-batch reproducibility, are required to meet regulatory expectations and ensure product safety and efficacy.

11. Future Perspectives

- **Need for nanoemulsion-based studies on Anthocephalus cadamba:** Despite promising pharmacological evidence, there is a lack of published nanoemulsion-based studies specifically

focusing on Anthocephalus cadamba bark extract. Future research should prioritize formulation and evaluation of nanoemulsions to fully explore its therapeutic potential.

- **Mechanistic and molecular investigations:** Advanced studies focusing on molecular mechanisms, signaling pathways, and target-specific actions will help in understanding the precise anti-inflammatory and analgesic effects of nanoemulsion-loaded phytoconstituents.
- **Clinical translation and human studies:** Preclinical success must be supported by well-designed clinical trials to establish safety, efficacy, and dosing in human subjects. Such studies are essential for translating herbal nanoemulsions into clinical practice.
- **Scale-up and commercialization:** Future efforts should address large-scale manufacturing, cost-effectiveness, and long-term stability of herbal nanoemulsion formulations to support commercialization and wider clinical use.
- **Regulatory framework development:** Development of clear regulatory guidelines for herbal nanomedicines will facilitate their approval and market entry. Collaborative efforts between researchers, industry, and regulatory authorities are necessary to establish standardized evaluation protocols.
- **Potential role in personalized and targeted therapy:** Nanoemulsion-based phytopharmaceuticals offer opportunities for targeted and personalized therapy, particularly in chronic pain and inflammatory disorders, where controlled and sustained drug delivery can significantly improve therapeutic outcomes.

12. CONCLUSION

Anthocephalus cadamba is a medicinally important plant with well-documented traditional and scientific evidence supporting its use in the management of pain



and inflammatory disorders. The bark of the plant contains a wide range of bioactive phytoconstituents, including alkaloids, flavonoids, triterpenoids, saponins, and phenolic compounds, which collectively contribute to its anti-inflammatory, analgesic, antioxidant, and wound-healing properties. Despite its promising pharmacological profile, the therapeutic application of conventional *A. cadamba* bark extract is limited by challenges such as poor solubility, low bioavailability, stability issues, and inconsistent therapeutic response.

Nanoemulsion-based drug delivery systems offer an effective strategy to overcome these limitations by enhancing solubility, improving bioavailability, protecting sensitive phytoconstituents from degradation, and ensuring more consistent therapeutic outcomes. The incorporation of *A. cadamba* bark extract into a nanoemulsion system has the potential to significantly improve its anti-inflammatory and analgesic efficacy, while also reducing dose-related variability and improving patient compliance.

Although existing evidence supports the pharmacological potential of *A. cadamba*, there remains a clear research gap in the development and evaluation of nanoemulsion-based formulations of this plant. Future studies focusing on formulation optimization, detailed mechanistic evaluation, safety assessment, and clinical validation are essential to establish its therapeutic relevance. Overall, nanoemulsion-based phytopharmaceutical development of *Anthocephalus cadamba* bark represents a promising and innovative approach for the effective management of pain and inflammatory disorders, with strong potential for future clinical and commercial application.

REFERENCES

1. Katz WA. Pain management in rheumatic diseases. *J Rheumatol Suppl.* 2002;70:15–21.
2. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ.* 2003;81(9):646–56.
3. Hawkey CJ. COX-2 inhibitors. *Lancet.* 1999;353(9149):307–14.
4. Rainsford KD. Anti-inflammatory drugs in the 21st century. *Subcell Biochem.* 2007;42:3–27.
5. Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines. *Phytother Res.* 2000;14(2):71–83.
6. Rates SMK. Plants as source of drugs. *Toxicon.* 2001;39(5):603–13.
7. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches. *Drug Discov Today.* 2009;14(15–16):804–11.
8. Kumar V, Singh PN, Bhattacharya SK. Anti-inflammatory and analgesic activity of *Anthocephalus cadamba*. *Indian J Pharmacol.* 2007;39(2):101–4.
9. Sivaraj A, et al. Phytochemical screening and antioxidant activity of *Anthocephalus cadamba*. *J Chem Pharm Res.* 2011;3(4):267–71.
10. Banerjee S, et al. Evaluation of wound healing activity of *Anthocephalus cadamba*. *Int J Pharm Sci Rev Res.* 2010;4(2):20–3.
11. Kokate CK, Purohit AP, Gokhale SB. *Pharmacognosy.* 55th ed. Pune: Nirali Prakashan; 2019.
12. Harborne JB. *Phytochemical Methods.* 3rd ed. London: Chapman & Hall; 1998.
13. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids. *Pharmacol Rev.* 2000;52(4):673–751.
14. Choudhary GP. Analgesic and anti-inflammatory potential of medicinal plants. *Pharmacogn Rev.* 2011;5(10):107–15.
15. Winter CA, Risley EA, Nuss GW. Carrageenan-induced edema. *Proc Soc Exp Biol Med.* 1962;111:544–7.
16. Turner RA. *Screening Methods in Pharmacology.* New York: Academic Press; 1965.
17. Kulkarni SK. *Handbook of Experimental Pharmacology.* 3rd ed. Delhi: Vallabh Prakashan; 2007.
18. Shakeel F, et al. Nanoemulsions as drug delivery systems. *Drug Dev Ind Pharm.* 2012;38(1):1–16.
19. Solans C, Solé I. Nano-emulsions. *Curr Opin Colloid Interface Sci.* 2012;17(5):246–54.
20. Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions. *Soft Matter.* 2016;12:2826–41.
21. Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nano-emulsions. *Adv Colloid Interface Sci.* 2004;108–109:303–18.
22. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying systems. *Adv Drug Deliv Rev.* 2010;62(3):309–26.



23. Gutiérrez JM, González C, Maestro A, Solè I, Pey CM, Nolla J. Nano-emulsions. *Langmuir*. 2008;24(21):12270–5.
24. Shakeel F, Ramadan W. Transdermal delivery of anticancer drug using nanoemulsion. *Colloids Surf B Biointerfaces*. 2010;75(2):356–62.
25. Lawrence MJ, Rees GD. Microemulsion-based media. *Adv Drug Deliv Rev*. 2000;45(1):89–121.
26. McClements DJ. Nanoemulsions vs microemulsions. *Soft Matter*. 2012;8:1719–29.
27. OECD. Guidelines for the Testing of Chemicals: Acute Oral Toxicity. Paris: OECD; 2001.
28. ICH Q8(R2). Pharmaceutical Development. International Council for Harmonisation; 2009.
29. EMA. Guideline on Quality of Herbal Medicinal Products. European Medicines Agency; 2011.
30. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions. *J Pharm Pharmacol*. 2004;56(7):827–40.

HOW TO CITE: Riya Jaitwar, Urwashi Ghughre, Diksha Bais, Nanoemulsion-Based Phytopharmaceutical Approaches of *Anthocephalus cadamba* for the Management of Pain and Inflammation: A Comprehensive Review, *J. Pharm. Sci.*, 2026, 2 (3), 650-659. <https://doi.org/10.5281/zenodo.19315881>

